Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a…
Analysis
FDA layoffs and priority review programme’s lapse disrupt rare disease pipeline
The GLP-1 drug shortage is over. What’s next for the compounders?
Can AI replace medical writers? Experts say not immediately
IRA holds the scope to shape pharma’s research strategy, say experts
Magazine: Are European biopharma manufacturers ‘nearshoring’?
Big pharma faces headwinds in China as vaccine sales decline
Rising Sirturo resistance highlights urgent need for new TB therapies
